You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in Japan

Jul 2011

Price: $2,400

About this Report

About this Report

Delivery method: instant download
Report format: PDF doc_pdf.png (download a sample)
Market statistics: Excel workbook doc_excel_table.png (download a sample)

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in Japan with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in Japan, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in Japan for free:

The Consumer Health in Japan market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in Japan?
  • What are the major brands in Japan?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Sample Analysis

EXECUTIVE SUMMARY

Slow but steady recovery from revised PAL implementation

With the introduction of the revised Pharmaceutical Affairs Law (PAL) in June 2009, the government categorised the available OTC products into three categories, according to risk. When the revised PAL was actually put into effect, it was found that the number of available pharmacists suited to sell the high risk Category 1 products – mainly consisting of switched OTC products – had been underestimated. This made a major dent in sales of Category 1 products, resulting in the downward trend in 2009. However, in 2010, as consumers got used to the new sales system and retailers undertook measures to minimise losses by optimising the allocation of pharmacists, consumer health returned to gradual positive growth.

Consumers focus on health maintenance rather than cure

Following the implementation of the compulsory health check in 2008, consumers have been more concerned to maintain their health. This can be seen in the increase in sales of sports nutrition, as new fat burning products were introduced to enhance the effects of exercise, which is becoming more popular among Japanese people. Also, herbal/traditional products, represented by kampo products that focus on gradually but fundamentally changing the body system, continued slow but steadily to gain popularity across categories. This trend has been supported by the fact that the economy is yet to recover, and tougher insurance policies have made consumers wary of unnecessary spending.

Competitive environment remained stagnant

There were no major mergers or acquisitions in the latter part of the review period within consumer health that would shake up the competitive environment. Neither were there significant new product launches that might change the rankings. Domestic players continue to dominate the market, and the leading players retained their positions in 2010. The conservative spending patterns of consumers have had some effect on this, as they have tended to stay loyal to the brands that they are familiar with, as they do not want to regret spending money on trying new brands only to find out that the familiar products were actually better.

Revised PAL makes only small impact on retail landscape

The government’s aim with the revised PAL was to promote self-medication, by allowing almost any store-based channels to sell OTC products, provided that a certified person attended the transaction. However, the government’s hope that this would be a smooth process proved to be overly optimistic, as it had overestimated the size of the qualified sales force. As a result, it aim of significantly broadening the sales channels for OTC products had not been achieved as of 2010.

Positive but slower growth expected over the forecast period

Factors such as the ageing of the population and people focusing on preventative measures and health maintenance should continue to drive positive growth of consumer health during the forecast period. However, the low birth rate are likely to restrict sales of child-specific products. Although the market is seeing newly emerging categories, such as cold sore products, as OTC switch approvals continue, they are likely to remain niche categories which will not have a significant impact on the overall development of the consumer health market. At the same time, the lost sales opportunities for Category 1 OTC products will continue over the forecast period, although this will slowly change as more suitably qualified staff become available.

Table of Contents

Table of Contents

Consumer Health in Japan - Industry Overview

EXECUTIVE SUMMARY

Slow but steady recovery from revised PAL implementation

Consumers focus on health maintenance rather than cure

Competitive environment remained stagnant

Revised PAL makes only small impact on retail landscape

Positive but slower growth expected over the forecast period

KEY TRENDS AND DEVELOPMENTS

Adding value through new formats and convenience

Desire for healthy and beautiful living continues

Promoting active ageing

Revised PAL plan to broaden sales channels a flop

Lack of pharmacists dampens sales of switched OTC products

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2005-2010
  • Table 2 Life Expectancy at Birth 2005-2010

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2005-2010
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2005-2010
  • Table 5 Consumer Health Company Shares by Value 2006-2010
  • Table 6 Consumer Health Brand Shares by Value 2007-2010
  • Table 7 Penetration of Private Label by Category 2005-2010
  • Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2005-2010
  • Table 9 Sales of Consumer Health by Category and Distribution Format: % Analysis 2010
  • Table 10 Forecast Sales of Consumer Health by Category: Value 2010-2015
  • Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2010-2015

APPENDIX

Consumer healthcare registration and classification

Self-medication/self-care and Preventative Medicine

Switches

  • Summary 1 OTC Healthcare Switches 2008-2010

DEFINITIONS

  • Summary 2 Research Sources

Consumer Health in Japan - Company Profiles

Daiichi Sankyo Healthcare Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 5 Daiichi Sankyo Healthcare Co Ltd: Competitive Position 2010

Fancl Corp in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 8 Fancl Corp: Competitive Position 2010

Hisamitsu Pharmaceutical Co Inc in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 11 Hisamitsu Pharmaceutical Co Inc: Competitive Position 2010

Kobayashi Pharmaceutical Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 14 Kobayashi Pharmaceutical Co Ltd: Competitive Position 2010

Otsuka Pharmaceutical Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 17 Otsuka Pharmaceutical Co Ltd: Competitive Position 2010

Rohto Pharmaceutical Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 20 Rohto Pharmaceutical Co Ltd: Competitive Position 2010

Sato Pharmaceutical Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 23 Sato Pharmaceutical Co Ltd: Competitive Position 2010

SSP Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 26 SSP Co Ltd: Competitive Position 2010

Taisho Pharmaceutical Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 29 Taisho Pharmaceutical Co Ltd: Competitive Position 2010

Takeda Chemical Industries Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 32 Takeda Chemical Industries Ltd: Competitive Position 2010

Adult Mouth Care in Japan - Category Analysis

HEADLINES

TRENDS

  • In 2009, sales of Category 1 products slumped, as a result of the revision of the Pharmaceutical Affairs Law, which came into effect in June of that year. However, the impact of the change began to abate in 2010, as consumers became more of aware of the channels in which these products were available. Furthermore, demographic factors, notably the ageing of the population, contributed to growth, as older people tend to suffer more from gum disease and gingivitis. As a result, sales of adult mouth care saw stronger growth in 2010 than in 2009.

SWITCHES

COMPETITIVE LANDSCAPE

  • Sato Pharmaceutical Co Ltd is the leading company in adult mouth care, with a 19% share in 2010. This is due to the company’s comprehensive coverage in adult mouth care. Its Access brand has a 17% share of adult mouth care and is a treatment for gum disease. Demand is increasing as Japan faces an ageing society. Furthermore, increasingly stressful and irregular lifestyles cause symptoms such as mouth ulcers, for which Sato Pharmaceutical offers the brand Aftach.

PROSPECTS

  • Adult mouth care has further growth potential over the forecast period, given that there are many people who suffer from mouth ulcers, as well as a growing incidence of gum disease due to the ageing society in Japan. Manufacturers are likely to introduce more user-friendly forms of treatment in order to bring new users into the category. At the same time, with the expansion of sales channels due to the revised Pharmaceutical Affairs Law, price competition is likely to heat up. Nevertheless, growth in volume consumption will be sufficient that category value will grow over the forecast period.

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2005-2010
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2005-2010
  • Table 14 Adult Mouth Care Company Shares by Value 2006-2010
  • Table 15 Adult Mouth Care Brand Shares by Value 2007-2010
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2010-2015
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2010-2015

Analgesics in Japan - Category Analysis

HEADLINES

TRENDS

  • Analgesics suffered a decline in sales in 2010, mainly for three reasons. Firstly, the decline represented a rebound from the strong demand related to the flu outbreak in 2009. Secondly, the revised Pharmaceutical Affairs Law, which limited Class 1 product sales to certain outlets with pharmacists, had a negative impact. Thirdly, there was a lack of new product launches to give dynamism to the category.

SWITCHES

COMPETITIVE LANDSCAPE

  • Hisamitsu Pharmaceutical remained the leading company in analgesics in 2010, with a 21% value share. Its leading position is due to its strength in topical analgesics, where it held a 32% value share in 2010. However, due to the revised Pharmaceutical Affairs Law, many of the new launches in 2009 which used the switched active ingredient diclofenac, such as Patex Petanship and Feitas Z, were put into Category 1, resulting in a dramatic drop in availability. As a result, although still the top player, the company’s share in topical analgesics dropped in 2010, resulting in a fall in its overall share in analgesics.

PROSPECTS

  • Analgesics is expected to experience value contraction of CAGR -1% in constant terms to reach ¥139 billion by 2015. The revised Pharmaceutical Affairs Law dramatically widened the retail channels for Category 2 and 3 OTC products. As a result of this, price competition among retailers is likely to increase over the forecast period, particularly with more private labels such as Aeon and Seven & I are entering the OTC arena joining forces with drugstore chains.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2005-2010
  • Table 19 Sales of Analgesics by Category: % Value Growth 2005-2010
  • Table 20 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2005-2010
  • Table 21 Analgesics Company Shares by Value 2006-2010
  • Table 22 Analgesics Brand Shares by Value 2007-2010
  • Table 23 Forecast Sales of Analgesics by Category: Value 2010-2015
  • Table 24 Forecast Sales of Analgesics by Category: % Value Growth 2010-2015

Calming and Sleeping in Japan - Category Analysis

HEADLINES

TRENDS

  • Calming and sleeping products continued to increase in sales in 2010. However, the lack of new products and stable pricing suggests that the category’s period of rapid growth is coming to an end.

SWITCHES

COMPETITIVE LANDSCAPE

  • SSP is the leading company in calming and sleeping products, with a 54% share of value in 2010. Its leading brand Drewell has a 49% share, with the brand having benefited from its early entry in 2003, which was followed into this category by other companies. Drewell was the first product based on diphenhydramine hydrochloride, which has recently been switched to OTC status. Since it has been on the market for more than three years, it was categorised as a Category 2 product under the revised Pharmaceutical Affairs Law, and was thus not impacted by the issues which impacted Category 1 products, notably more limited availability.

PROSPECTS

  • Calming and sleeping products are predicted to show a 3% CAGR in constant value terms over the forecast period. This is lower than the 9% CAGR seen in the review period, but given this category’s rapid growth from 2003, such a slowdown is inevitable as it matures. Although growth will be slower compared to the review period, demand of calming and sleeping product should continue to increase over the forecast period, as cases of irregular sleep caused by high stress levels show no sign of decreasing. So far, there are no Category 1 products in the category, and the risk of any health issues are relatively low, but if there should be a case where ingredients such as diphenhydramine hydrochloride are deemed as hazardous to health, the expected upward trend could be reversed.

CATEGORY DATA

  • Table 25 Sales of Calming and Sleeping: Value 2005-2010
  • Table 26 Sales of Calming and Sleeping: % Value Growth 2005-2010
  • Table 27 Calming and Sleeping Company Shares by Value 2006-2010
  • Table 28 Calming and Sleeping Brand Shares by Value 2007-2010
  • Table 29 Forecast Sales of Calming and Sleeping: Value 2010-2015
  • Table 30 Forecast Sales of Calming and Sleeping: % Value Growth 2010-2015

Cough, Cold and Allergy (Hay Fever) Remedies in Japan - Category Analysis

HEADLINES

TRENDS

  • Cough, cold and allergy remedies sales showed only a marginal value increase of 0.1% reaching ¥293 billion in 2010. This subsector showed a contraction in 2009, impacted by the H1N1 flu which continued till March 2010. This is because most people consulted doctors to obtain prescription drugs instead of OTC products. By March 2010 the peak of the pandemic had past the peak, but consumers continued to be cautious about it, resulting in an almost flat growth.

SWITCHES

COMPETITIVE LANDSCAPE

  • Taisho Pharmaceutical Co Ltd was the leading player in cough, cold and allergy remedies in 2010, with a value share of 19% in 2010. This position is due to its broad product portfolio, providing comprehensive coverage of various symptoms, mainly with its core brand Pablon. The company experienced an increase value shares in 2010 mainly due to their Pablon brand showing a steady performance despite the slow demand for cough, cold and allergy remedies.

PROSPECTS

  • Cough, cold and allergy remedies is expected to show a positive CAGR of 0.7% in constant value terms over the forecast period. Demand for allergy remedies should continue similar to the review period with oral decongestants driving growth with a CAGR of 3%, increasing by ¥2.8 billion over the forecast period. This will be due to increasing demand for products that provide a convenient solution.

CATEGORY DATA

  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 33 Sales of Decongestants by Category: Value 2005-2010
  • Table 34 Sales of Decongestants by Category: % Value Growth 2005-2010
  • Table 35 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 36 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2006-2010
  • Table 38 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2007-2010
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2010-2015
  • Table 40 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2010-2015

Digestive Remedies in Japan - Category Analysis

HEADLINES

TRENDS

  • Sales of digestive remedies continued to shrink in 2010, mainly due to a downward trend in products that are aimed at curing indigestion. Conversely, products focusing on conditioning the internal system such as antiflatulents performed well. Also, the fact that the Japanese economy has yet to recover, reflected in conservative spending habits, as well as a shift towards healthier lifestyles, including diets. Another issue which impacted the category was the revised Pharmaceutical Affairs Law, which came into effect in June 2009, resulting in a decline in sales of Category 1 products, notably H2 blockers.

SWITCHES

COMPETITIVE LANDSCAPE

  • Digestive remedies is dominated by domestic players, with no international players having a strong position. Taisho Pharmaceutical is the leading player in digestive remedies, with a 13% value share in 2010. The company has a comprehensive product portfolio in digestive remedies, and this contributes to its strong position. Although the company suffered in categories such as H2 blockers in the second half of 2009 and 2010, due to the revised Pharmaceutical Affairs Law, it has a strong foundation with established brands such as Taisho Kampo Ichoyaku, which is popular among consumers who prefer herbal/traditional ingredients. With its comprehensive coverage of both the standard and herbal/traditional categories, the company minimised the impact of the revised Pharmaceutical Affairs Law, and thus saw the largest increase in share in 2010.

PROSPECTS

  • Fundamental factors such as an ageing and shrinking population will continue to have an impact on sales of digestive remedies, which are predicted to show a contraction over the forecast period. The economic situation has yet to show signs of significant improvement, and overindulgence in alcohol drinks and food is unlikely to see growth. However, the unstable social and economic situation could increase stress levels, resulting in an increase in sales of products targeted at stress-related symptoms. Also, health consciousness should continue to rise over the forecast period, resulting in products which focus on maintaining intestinal health performing relatively well.

CATEGORY DATA

  • Table 41 Sales of Digestive Remedies by Category: Value 2005-2010
  • Table 42 Sales of Digestive Remedies by Category: % Value Growth 2005-2010
  • Table 43 Digestive Remedies Company Shares by Value 2006-2010
  • Table 44 Digestive Remedies Brand Shares by Value 2007-2010
  • Table 45 Forecast Sales of Digestive Remedies by Category: Value 2010-2015
  • Table 46 Forecast Sales of Digestive Remedies by Category: % Value Growth 2010-2015

Ear Care in Japan - Category Analysis

HEADLINES

TRENDS

  • Ear care showed a growth rate of 5% in 2010, which was slower than the review period’s CAGR of 77% that was due to the introduction of Naripitan in 2006. This indicates that the category has entered a period of slower but steady growth, driven largely by the ageing of Japan’s population. Ear care is almost entirely dependent on sales of Kobayashi Pharmaceutical’s Naripitan, so the performance of the category is a direct reflection of the brand’s growth.

SWITCHES

COMPETITIVE LANDSCAPE

  • Kobayashi Pharmaceuticals is the dominant player in ear care, with a 99% value share. Its brand Naripitan continues to dominate ear care by increasing sales from new users, reaching a value of just below ¥1.4 billion in 2010. The ageing of Japanese society is contributing to growth, as tinnitus becomes more common as people age. For consumers who suffer from tinnitus, Naripitan is the only product available in the consumer healthcare market. There were no new products that launched in this category in 2010, and thus the competitive landscape remains unchanged in that year.

PROSPECTS

  • Ear care is projected to see a 4% constant value CAGR over the forecast period. This is a slight slowdown compared with the 5% growth seen in 2010. Growth will continue, although at a slow rate as the product lifecycle continues to move towards maturity. According to a Kobayashi survey, around 14% of those in their 50s experience ringing in their ears at least once a week. With an increasing base of repeat users, Naripitan should continue to see its sales grow, in line with the ageing of society in Japan.

CATEGORY DATA

  • Table 47 Sales of Ear Care: Value 2005-2010
  • Table 48 Sales of Ear Care: % Value Growth 2005-2010
  • Table 49 Ear Care Company Shares by Value 2006-2010
  • Table 50 Ear Care Brand Shares by Value 2007-2010
  • Table 51 Forecast Sales of Ear Care: Value 2010-2015
  • Table 52 Forecast Sales of Ear Care: % Value Growth 2010-2015

Eye Care in Japan - Category Analysis

HEADLINES

TRENDS

  • 2010 saw a decline in eye care sales, due mainly to less cedar pollen during the hay fever season. This resulted in a sharp contraction in sales of allergy related products. At the same time, value-added products increasingly appealed to consumers, particularly with the ageing of the population, and the increasing use of computers. Added value products such as those which can be applied without taking off contact lenses also showed favourable results. Products without such added value features were exposed to price competition, resulting in declining sales value.

SWITCHES

COMPETITIVE LANDSCAPE

  • The leading company in eye care in 2010 continued to be Rohto Pharmaceutical, with a 33% value share. At the end of 2009, Rohto launched C-Cube Clear Flash AL, the first antihistamine eye drop that can be used with soft contact lens to prepare for the coming hay fever season. It caters for the demand among contact lens users who need relief from itchiness due to allergy symptoms, without the hassle of removing their lenses. The company continues to maintain its position as the leading company by providing such value-added products to avoid direct competition with cheaper alternatives, such as private label offerings.

PROSPECTS

  • Over the forecast period, eye care is expected to see a slight decline in sales in constant value terms. The main reason for the decline will be an expected fall in the average price. This is due to intensifying price competition among retail channels, following the revision of the Pharmaceutical Affairs Law. Private label offerings are expected to increase their presence in the wider consumer health market, and this is likely to happen in eye care. Switched OTC products with added value might be introduced over the forecast period, but are unlikely to have a sufficient impact to boost the average unit price overall.

CATEGORY DATA

  • Table 53 Sales of Eye Care by Category: Value 2005-2010
  • Table 54 Sales of Eye Care by Category: % Value Growth 2005-2010
  • Table 55 Standard Eye Care by Type: % Value Breakdown 2007-2010
  • Table 56 Eye Care Company Shares by Value 2006-2010
  • Table 57 Eye Care Brand Shares by Value 2007-2010
  • Table 58 Forecast Sales of Eye Care by Category: Value 2010-2015
  • Table 59 Forecast Sales of Eye Care by Category: % Value Growth 2010-2015

Herbal/Traditional Products in Japan - Category Analysis

HEADLINES

TRENDS

  • Herbal/traditional products grew marginally in current value terms in 2010, which represented a slight recovery compared with an annual average decline of 1% over the review period. This was driven by the strong consumer interest in kampo remedies. However, the decline in herbal analgesics was due to consumers looking for standard products with more immediate effect for pain killers while a milder effect is acceptable in other categories, as consumers perceive herbal/traditional products to be safer, with fewer side effects, although this is not necessarily actually the case.

COMPETITIVE LANDSCAPE

  • Miki Corp led the herbal/traditional products environment in Japan in 2010, with a 15% value share. Its sales are mainly driven by its Miki Prune product. However, the brand’s share is slowly declining, as other prune products are now available through store-based retail channels, while Miki Corp is sticking to its direct sales format – a channel which is regarded with some suspicion by many Japanese consumers. Furthermore, mineral supplements that contain iron are also available as an alternative to prune extract.

PROSPECTS

  • Sales of herbal/traditional products are expected to decline marginally in constant value terms over the forecast period. Within herbal/traditional products, Kampo products, which are certified as pharmaceuticals, are likely to perform better than the normal herbal/traditional dietary supplements, due to consumer perceptions that herbal/traditional dietary supplements are essentially health foods.

CATEGORY DATA

  • Table 60 Sales of Herbal/Traditional Products: Value 2005-2010
  • Table 61 Sales of Herbal/Traditional Products: % Value Growth 2005-2010
  • Table 62 Herbal/Traditional Products Company Shares 2006-2010
  • Table 63 Herbal/Traditional Products Brand Shares 2007-2010
  • Table 64 Forecast Sales of Herbal/Traditional Products: Value 2010-2015
  • Table 65 Forecast Sales of Herbal/Traditional Products: % Value Growth 2010-2015

Medicated Skin Care in Japan - Category Analysis

HEADLINES

TRENDS

  • Medicated skin care saw 2% value growth in 2010, which was slightly slower than the review period CAGR of 3%. The slower growth compared with the review period CAGR was mainly due to the revised Pharmaceutical Affairs Law implemented in 2009, restricting sales of Category 1 products, which are typically higher priced. This category includes ingredients such as acyclovir and miconazole nitrate, which were switched to OTC in 2007 and 2008, respectively. However, 2010’s growth rate was still higher than the previous year’s growth rate of 1%, which was impacted by the effects of the financial crisis on the economy, as well as the Pharmaceutical Affairs Law revision.

SWITCHES

COMPETITIVE LANDSCAPE

  • Taisho Pharmaceutical Co Ltd continues to be the leading player in medicated skin care, with an 18% value share in 2010. The company was also the fastest growing company in medicated skin care, increasing its share by one percentage point on the previous year. The company has a strong presence in various key skin care categories. It also has a very strong presence in certain dynamic niches, such as hair loss treatments, cold sore treatments and vaginal antifungals. This enabled the company to achieve strong growth despite the overall medicated skin care category being rather undynamic.

PROSPECTS

  • Medicated skin care is expected to grow by a CAGR of 1% in constant value terms over the forecast period. The growth in newer categories such as vaginal antifungals and cold sore remedies will slow down. As of 2010, these are Category 1 products but after the trial period, they may be changed to Category 2 products, resulting in wider distribution which might boost sales.

CATEGORY DATA

  • Table 66 Sales of Medicated Skin Care by Category: Value 2005-2010
  • Table 67 Sales of Medicated Skin Care by Category: % Value Growth 2005-2010
  • Table 68 Acne Treatments by Format: % Value Breakdown 2005-2010
  • Table 69 Medicated Skin Care Company Shares by Value 2006-2010
  • Table 70 Medicated Skin Care Brand Shares by Value 2007-2010
  • Table 71 Acne Treatments Brand Shares by Value 2007-2010
  • Table 72 Hair Loss Treatments Brand Shares by Value 2007-2010
  • Table 73 Forecast Sales of Medicated Skin Care by Category: Value 2010-2015
  • Table 74 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2010-2015

Sports Nutrition in Japan - Category Analysis

HEADLINES

TRENDS

  • Sports nutrition saw a value increase of 6% in 2010, compared to an annual average decline of 2% over the review period as a whole. With Ajinomoto’s Amino Vital accounting for more than half of category sales, the category’s performance is strongly linked to the performance of the brand. In 2009, in the aftermath of the financial crisis, the brand’s sales suffered as consumers cut down on their spending. However, with the damage of the financial crisis fading, alongside the current exercise boom and new product development, sports nutrition managed to recover from the downward trend which characterised the earlier years of the review period.

COMPETITIVE LANDSCAPE

  • Ajinomoto continues to be the leading player in sports nutrition, with a 57% value share in 2010. The company dominates the amino acids category with its Amino Vital brand. As consumer knowledge of sports nutrition products increases, the importance of amino acid is being more widely acknowledged, and this contributed to the company’s share returning to growth in 2010. Ajinomoto is also strong in sports nutrition bars, in which its Amino Vital Sports products is popular.

PROSPECTS

  • Sports nutrition is predicted to show positive growth over the forecast period, with a CAGR of 2% in constant value terms. This will be largely driven by less hardcore athletes who engage in exercise to maintain health and keep slim. With compulsory health checks and concerns about metabolic syndrome, more people are acknowledging the importance of regular exercise. Sports activities, such as jogging, are being more regularly incorporated into people’s lifestyles. These factors should work in favour of this category, contributing to steady growth over the forecast period.

CATEGORY DATA

  • Summary 33 Sports Nutrition: Brand Ranking By Format 2010
  • Table 75 Sales of Sports Nutrition: Value 2005-2010
  • Table 76 Sales of Sports Nutrition: % Value Growth 2005-2010
  • Table 77 Sports Nutrition By Format: % Value Breakdown 2007-2010
  • Table 78 Sports Nutrition Company Shares 2006-2010
  • Table 79 Sports Nutrition Brand Shares 2007-2010
  • Table 80 Forecast Sales of Sports Nutrition: Value 2010-2015
  • Table 81 Forecast Sales of Sports Nutrition: % Value Growth 2010-2015

Vitamins and Dietary Supplements in Japan - Category Analysis

HEADLINES

TRENDS

  • Vitamins and dietary supplements saw an increase of just under 1% in 2010, which was higher than the review CAGR. Growth was supported by increased sales of both vitamins and dietary supplements. The main growth drivers were anti-ageing and beauty, but other products focusing on wellbeing, such as energy and eye health, also contributed to growth, which, overall, has been supported by more hectic modern lifestyles, including heavy computer usage.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Taisho Pharmaceutical continued to be the leading company in vitamins and dietary supplements in 2010 with an 8% value share. However, the company’s share dropped, as tonics and bottled nutritive drinks continued to see a downturn. The company has close to 50% of the bottled nutritive drinks category, with its Lipovitan brand. In view of shrinking sales, the company introduced Lipovitan FB in March 2010, which includes carnitine chloride, an ingredient to enhance fat burning.

PROSPECTS

  • Sales of vitamins and dietary supplements are expected to grow only slowly over the forecast period. Japan is an ageing society, with more women becoming career-focused. As such, the category will be driven by the continuing demand for products focused on beauty, anti-ageing and wellbeing. Due to the maturity of the category, products focusing on particular use/consumer groups will continue to be launched, as well as value-added products, such as those with fat-burning and other slimming properties.

CATEGORY DATA

  • Summary 34 Dietary Supplements: Brand Ranking by Positioning 2010
  • Table 82 Sales of Vitamins and Dietary Supplements by Category: Value 2005-2010
  • Table 83 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2005-2010
  • Table 84 Dietary Supplements by Positioning 2005-2010
  • Table 85 Vitamins and Dietary Supplements Company Shares by Value 2006-2010
  • Table 86 Vitamins and Dietary Supplements Brand Shares by Value 2007-2010
  • Table 87 Vitamins Brand Shares by Value 2007-2010
  • Table 88 Dietary Supplements Brand Shares by Value 2007-2010
  • Table 89 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2010-2015
  • Table 90 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2010-2015

Weight Management in Japan - Category Analysis

HEADLINES

TRENDS

  • Weight management continued to contract in 2010, by 6%, which was a faster rate of decline than the review period average of 3%. This was mainly due to people relying less on such products to lose weight, and instead moving towards sliming down by taking more exercise. More conservative spending, as the Japanese economy has yet to recover, also impacted sales of weight management products. In addition manufacturers lacked new products to drive category growth.

COMPETITIVE LANDSCAPE

  • Fancl Corp was the leading company in weight management in 2010, with a 17% value share. The company is the leading player in the largest category, weight loss supplements, with a share of 29%. Although the company’s brands Calolimit and Perfect Slim saw sales decline in 2010, the company managed to secure a higher share in 2010, as the rate of decline was slower than that of the category overall.

PROSPECTS

  • Weight management is predicted contract at CAGR of 1.7% in constant value terms over the forecast period. Sales will be hampered by the fact that Japan’s economy has yet to see a significant recovery, thus consumer spending in general is likely to be conservative. Running and walking are increasingly becoming established activities in Japan as a cost-effective way of keeping fit and maintaining or reducing weight. The health trend is expected to continue but, considering the economic situation, it is unlikely that more people will opt to rely on weight management products. Meal replacement slimming products are predicted to show the fastest decline over the forecast period.

CATEGORY DATA

  • Table 91 Sales of Weight Management: Value 2005-2010
  • Table 92 Sales of Weight Management: % Value Growth 2005-2010
  • Table 93 Weight Management Company Shares 2006-2010
  • Table 94 Weight Management Brand Shares 2007-2010
  • Table 95 Forecast Sales of Weight Management: Value 2010-2015
  • Table 96 Forecast Sales of Weight Management: % Value Growth 2010-2015

Wound Care in Japan - Category Analysis

HEADLINES

TRENDS

  • Wound treatments saw value growth of 1% in 2010. Growth was driven by increased sales of sticking plaster products, due to their convenience. However, growth in sticking plasters slowed to 1% in 2010, as consumers shifted to cheaper products, such as private labels, to cut down on spending. Gauze, tapes and other wound care continued to show a decline, of 2%, due to their being less convenient to use than sticking plasters. The presence of first aid kits is negligible in Japan, due to products such as wound treatments being commonly available at convenience stores, which can readily be found across Japan.

COMPETITIVE LANDSCAPE

  • Johnson & Johnson KK continued to be the leading player in 2010, with a 22% value share. Despite the general trend of trading down, the company’s value-added products, such as Band-Aid Kizu Power Pad, which accelerates the healing process, continues to grow in popularity. However, in terms of new product development, the company did not launch anything particularly innovative in the latter part of the review period, with new launches being limited to variants of the Kizu Power Pad, focused on blisters caused by footwear, and a relaunch of its children’s products.

PROSPECTS

  • Sales of wound treatments are predicted to grow only marginally over the forecast period in constant value terms, with growth being rather slower than the review period constant value CAGR. However the category will continue to show a positive performance, as the trend of consumers using sticking plaster products as an alternative to topical germicidals/antiseptics is likely to continue. However, growth will slow down, mainly due to a decline in unit prices caused by consumers shifting to cheaper products, including private labels, given the uncertain economic situation.

CATEGORY DATA

  • Table 97 Sales of Wound Care by Category: Value 2005-2010
  • Table 98 Sales of Wound Care by Category: % Value Growth 2005-2010
  • Table 99 Wound Care Company Shares by Value 2006-2010
  • Table 100 Wound Care Brand Shares by Value 2007-2010
  • Table 101 Forecast Sales of Wound Care by Category: Value 2010-2015
  • Table 102 Forecast Sales of Wound Care by Category: % Value Growth 2010-2015

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Child-Specific Analgesics
            • Child-Specific Acetaminophen
            • Child-Specific Aspirin
            • Child-Specific Combination Products - Analgesics
            • Child-Specific Diclofenac
            • Child-Specific Dipyrone
            • Child-Specific Ibuprofen
            • Child-Specific Ketoprofen
            • Child-Specific Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Child-Specific Cough, Cold and Allergy Remedies
          • Child-Specific Allergy Remedies
          • Child-Specific Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Child-Specific Digestive Remedies
          • Child-Specific Diarrhoeal Remedies
          • Child-Specific Indigestion and Heartburn Remedies
          • Child-Specific Laxatives
          • Child-Specific Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Acne Treatments
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Child-Specific Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
    • Vitamins and Dietary Supplements
      • Child-Specific Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Agaricus
            • Isoflavones
            • Microalgae
            • Prune Extract
            • Ukon
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
            • Amino Acid
            • Other Other Non-Herbal Dietary Supplements
      • Tonics and Bottled Nutritive Drinks
      • Vitamins
        • Multivitamins
        • Single Vitamins
          • Vitamin A
          • Vitamin B
          • Vitamin C
          • Vitamin D
          • Vitamin E
          • Other Single Vitamins
    • Weight Management
      • Meal Replacement Slimming
      • OTC Obesity
      • Slimming Teas
      • Weight Loss Supplements
      • Other Slimming Products
    • Herbal/Traditional Products
      • Herbal/Traditional Analgesics
      • Herbal/Traditional Calming and Sleeping Products
      • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
      • Herbal/Traditional Digestive Remedies
      • Herbal/Traditional Medicated Skin Care
      • Herbal/Traditional Medicinal Teas
      • Herbal/Traditional Smoking Cessation Aids
      • Herbal/Traditional Child-Specific Dietary Supplements
      • Herbal/Traditional Dietary Supplements
      • Herbal/Traditional Tonics and Bottled Nutritive Drinks
    • Allergy Care
      • Allergy Eye Care
      • Antihistamines/Allergy Remedies (Systemic)
      • Child-Specific Allergy Remedies
      • Topical Allergy Remedies/Antihistamines
    • Child-Specific Consumer Health
      • Child-Specific Analgesics
        • Child-Specific Acetaminophen
        • Child-Specific Aspirin
        • Child-Specific Combination Products - Analgesics
        • Child-Specific Diclofenac
        • Child-Specific Dipyrone
        • Child-Specific Ibuprofen
        • Child-Specific Ketoprofen
        • Child-Specific Naproxen
      • Child-Specific Cough, Cold and Allergy Remedies
        • Child-Specific Allergy Remedies
        • Child-Specific Cough/Cold Remedies
      • Child-Specific Digestive Remedies
        • Child-Specific Diarrhoeal Remedies
        • Child-Specific Indigestion and Heartburn Remedies
        • Child-Specific Laxatives
        • Child-Specific Motion Sickness Remedies
      • Child-Specific Medicated Skin Care
      • Nappy (Diaper) Rash Treatments
      • Child-Specific Vitamins and Dietary Supplements

Statistics Included

Statistics Included

For each category and subcategory you will receive the following data in Excel format:

From Passport

  • Market sizes
  • Company shares
  • Brand shares
  • Distribution
  • Analysis by format
  • Analysis by positioning
  • Analysis by type
  • Herbal/traditional vs standard
  • Pricing
  • Smoking population - number of adult smokers
  • Smoking prevalence - % of adult population

Market size details:

  • Retail volume
  • Retail volume % growth
  • Retail volume per capita
  • Retail value retail selling price % growth
  • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price real (constant 2008) prices % growth
  • Retail value retail selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price % growth
  • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price real (constant 2008) prices % growth
  • Retail value manufacturer selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price nominal (current) prices % growth
  • Retail value retail selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price nominal (current) prices % growth
  • Retail value manufacturer selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY

Methodology

Methodology

Global insight and local knowledge

With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

Industry specialists

Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

Country and regional analysts

Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

In-country research network

To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

Research Methodology

Our research methods

Each Euromonitor International industry report is based on a core set of research techniques:

Desk research

With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

  • National statistics offices governmental and official sources
  • National and international trade press
  • National and international trade associations
  • Industry study groups and other semi-official sources
  • Company financials and annual reports
  • Broker reports
  • Online databases
  • The financial, business and mainstream press

Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

Store checks

Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

  • Place: We track products in all relevant channels, selective and mass, store and non-store
  • Product: What are innovations in products, pack sizes and formats?
  • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
  • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

Trade survey

Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

Trade surveys allow us to:

  • Fill gaps in available published data per company
  • Generate a consensus view of the size, structure and strategic direction of the category
  • Access year-in-progress data where published sources are out of date
  • Evaluate the experts’ views on current trends and market developments

In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

Company analysis

At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

Forecasts

Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

Data validation

All data is subjected to an exhaustive review process, at country, regional and global levels.

The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

Market analysis

Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

my pages

Want to find out more about this report?

RELATED

Country Report

Consumer Lifestyle

Future Demographic

Country Report